Outcomes of non-high grade serous carcinoma after neoadjuvant chemotherapy for advanced-stage ovarian cancer: a Korean gynecologic oncology group study (OV 1708)

High Grade ◽

Advanced Stage ◽

Oncology Group ◽

A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D

Journal of Gynecologic Oncology ◽

10.3802/jgo.2019.30.e112 ◽

2019 ◽

Vol 30 (6) ◽

Cited By ~ 2

Author(s):

Jung-Yun Lee ◽

Jae Weon Kim ◽

Myong Cheol Lim ◽

Sunghoon Kim ◽

Hee Seung Kim ◽

...

Keyword(s):

Ovarian Cancer ◽

Neoadjuvant Chemotherapy ◽

Phase Ii ◽

Phase Ii Study ◽

Gynecologic Oncology ◽

Advanced Stage ◽

Oncology Group ◽

Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: A gynecologic oncology group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2012.01.008 ◽

2012 ◽

Vol 125 (2) ◽

pp. 421-426 ◽

Cited By ~ 32

Author(s):

Jennifer M. Rubatt ◽

Kathleen M. Darcy ◽

Chunqiao Tian ◽

Franco Muggia ◽

Rajiv Dhir ◽

...

Keyword(s):

Ovarian Cancer ◽

Clinical Outcomes ◽

Gynecologic Oncology ◽

Advanced Stage ◽

Oncology Group ◽

Oncology Group Study ◽

Pre Treatment ◽

Tumor Expression

Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2021.11.013 ◽

2021 ◽

Author(s):

Nefertiti C. duPont ◽

Danielle Enserro ◽

Mark F. Brady ◽

Katherine Moxley ◽

Joan L. Walker ◽

...

Keyword(s):

Ovarian Cancer ◽

Gynecologic Oncology ◽

Prognostic Significance ◽

Advanced Stage ◽

Oncology Group ◽

Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2011.11.022 ◽

2012 ◽

Vol 124 (3) ◽

pp. 575-581 ◽

Cited By ~ 56

Author(s):

Chunqiao Tian ◽

Christine B. Ambrosone ◽

Kathleen M. Darcy ◽

Thomas C. Krivak ◽

Deborah K. Armstrong ◽

...

Keyword(s):

Ovarian Cancer ◽

Clinical Outcomes ◽

Gynecologic Oncology ◽

Advanced Stage ◽

Common Variants ◽

Oncology Group ◽

Corrigendum to “Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study” [Gynecol. Oncol. 151 (2018) 18–23]

Gynecologic Oncology ◽

10.1016/j.ygyno.2018.10.022 ◽

2019 ◽

Vol 152 (1) ◽

pp. 220

Author(s):

Alexander B. Olawaiye ◽

James J. Java ◽

Thomas C. Krivak ◽

Michael Friedlander ◽

David G. Mutch ◽

...

Keyword(s):

Ovarian Cancer ◽

Adjuvant Chemotherapy ◽

Gynecologic Oncology ◽

Advanced Stage ◽

Oncology Group ◽

Oncology Group Study ◽

Dose Modification ◽

Chemotherapy Dose

Association between the N-terminally truncated (ΔN) p63α (ΔNp63α) isoform and debulking status, VEGF expression and progression-free survival in previously untreated, advanced stage epithelial ovarian cancer: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2009.07.035 ◽

2009 ◽

Vol 115 (3) ◽

pp. 424-429 ◽

Cited By ~ 3

Author(s):

Elizabeth L. Jewell ◽

Kathleen M. Darcy ◽

Alan Hutson ◽

Paula S. Lee ◽

Laura J. Havrilesky ◽

...

Keyword(s):

Ovarian Cancer ◽

Gynecologic Oncology ◽

Progression Free Survival ◽

Advanced Stage ◽

Oncology Group ◽

Vegf Expression ◽

Free Survival ◽

Loss of p16 in advanced stage epithelial ovarian cancer is associated with chemoresistant disease, suboptimal debulking and poor progression-free survival: A Gynecologic Oncology Group study.

Gynecologic Oncology ◽

10.1016/j.ygyno.2011.12.084 ◽

2012 ◽

Vol 125 ◽

pp. S37

Author(s):

A. Wallace ◽

K. Darcy ◽

A. Alvarez-Secord ◽

A. Hutson ◽

D. Tritchler ◽

...

Keyword(s):

Ovarian Cancer ◽

Gynecologic Oncology ◽

Progression Free Survival ◽

Advanced Stage ◽

Oncology Group ◽

Free Survival ◽

Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival in advanced stage ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2016.09.005 ◽

2016 ◽

Vol 143 (3) ◽

pp. 511-515 ◽

Cited By ~ 4

Author(s):

Peter G. Rose ◽

James J. Java ◽

Mark A. Morgan ◽

Angeles Alvarez-Secord ◽

Joshua P. Kesterson ◽

...

Keyword(s):

Ovarian Cancer ◽

Overall Survival ◽

Cytoreductive Surgery ◽

Gynecologic Oncology ◽

Advanced Stage ◽

Oncology Group ◽

Disease Extent ◽

Oncology Group Study ◽

Secondary Cytoreductive Surgery

Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2018.03.043 ◽

2018 ◽

Vol 149 (3) ◽

pp. 525-530 ◽

Cited By ~ 11

Author(s):

Ramez N. Eskander ◽

James Kauderer ◽

Krishnansu S. Tewari ◽

Robert S. Mannel ◽

Robert E. Bristow ◽

...

Keyword(s):

Ovarian Cancer ◽

Residual Disease ◽

Gynecologic Oncology ◽

Radiographic Evaluation ◽

Advanced Stage ◽

Oncology Group ◽

Nomogram predicting individual survival following recurrence in advanced stage high-grade ovarian cancer from NRG Oncology/Gynecologic Oncology Group randomized trials of platinum and paclitaxel

Gynecologic Oncology ◽

10.1016/j.ygyno.2017.03.147 ◽

2017 ◽

Vol 145 ◽

pp. 61

Author(s):

P.G. Rose ◽

J. Java ◽

D.M. O'Malley ◽

M.A. Geller ◽

F.M. Muggia ◽

...

Keyword(s):

Ovarian Cancer ◽

Randomized Trials ◽

Gynecologic Oncology ◽

High Grade ◽

Advanced Stage ◽

Oncology Group ◽

Group Randomized Trials ◽

Individual Survival